5773-58-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5773-58-0,3-Methylpiperidin-4-one,as a common compound, the synthetic route is as follows.
A solution of N-(7-chloropyrazolo[ 1 ,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2- yl)benzamide (2D, 50 mg,0.151 mmol) and 3-methylpiperidin-4-one (34 mg,0.302 mmol) in NMP (0.950 mL) was stirred at 850C overnight. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC, 30-55% ( MeCN/H2O gradient + 0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (34 mg, 56%). 1H NMR (400 MHz, DMSO-J6) delta ppm 1.02 (d, J=6.57 Hz, 3 H) 1.46 (s, 6 H) 2.74 – 2.97 (m, 2 H) 3.30 (t, J=I 1.87 Hz, 1 H) 3.57 – 3.69 (m, 1 H) 4.56 – 4.70 (m, 2 H) 6.38 (d, J=2.27 Hz, 1 H) 7.48 (s, 1 H) 7.60 (d, J=8.59 Hz, 2 H) 8.00 (d, J=8.59 Hz, 2 H) 8.13 (d, J=2.27 Hz, 1 H) 10.93 (s, 1 H). ESI-MS: m/z 408.2 (M+H)+.
As the paragraph descriping shows that 5773-58-0 is playing an increasingly important role.
Reference：
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; WO2009/123986; (2009); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem